IMMUNOGLOBULIN G4-KAPPA, ANTI-(HUMAN ADP-RIBOSYL CYCLASE/CYCLIC ADP-RIBOSE HYDROLASE 1 (EC:3.2.2.6) (ADPRC 1/CADRP HYDROLASE 1, CELL SURFACE ANTIGEN CD38)), HUMANIZED MONOCLONAL ANTIBODY, FUSED AT EACH C-TERMINUS OF THE HEAVY CHAINS (1-447, 1''-447'') TO ATTENUATED HUMAN INTERFERON .ALPHA.-2B (IFN.ALPHA.2B) VARIANT (K23>R470, T106>A553, A145>D592) (448-612, 448''-612''); GAMMA4 HEAVY CHAIN HUMANIZED FUSED TO IFN.ALPHA.2B (1-612) (VH (HOMO SAPIENS IGHV1-69-2*01 (90.7%)-(IGHD)-IGHJ4*01 (85.7%)) CDRIMGT (8.8.13) (26-33.51-58.97-109) (1-120)-HOMO SAPIENS IGHG4*01, G4V5 H P10 (CH1 (121-218), HINGE 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(121-447), FUSED TO IFN.ALPHA.2B K23>R (470), T106>A (553), A145>D (592) (448-612)),(134-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-33*01 (83.2%)-IGKJ4*01 (100%)) CDR-IMGT (6.3.9) (27-32.50-52.89-97) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (226-226'':229-229'')-BISDISULFIDE; PRODUCED IN CHINESE HAMSTER OVARY (CHO) K1SV CELLS, GLYCOFORM ALFA
Neoplasms
Rating breakdown
- Clinical Evidence
- 11/ 100
- Competitive Position
- 65/ 100
Competitive context
928 Active assets in the Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB Astellas Pharma Inc | Phase 2 | BBB |
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi | Phase 4 | BB |
Inno-206 The First Affiliated Hospital of Soochow University | Phase 2/3 | BB |
DINITROGEN MONOXIDE Medical College of Wisconsin | Phase 4 | BB |
Glycopyrrolate Medical College of Wisconsin | Phase 4 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HUMAN ADP-RIBOSYL CYCLASE/CYCLIC ADP-RIBOSE HYDROLASE 1 (EC:3.2.2.6) (ADPRC 1/CADRP HYDROLASE 1, CELL SURFACE ANTIGEN CD38)), HUMANIZED MONOCLONAL ANTIBODY, FUSED AT EACH C-TERMINUS OF THE HEAVY CHAINS (1-447, 1''-447'') TO ATTENUATED HUMAN INTERFERON .ALPHA.-2B (IFN.ALPHA.2B) VARIANT (K23>R470, T106>A553, A145>D592) (448-612, 448''-612''); GAMMA4 HEAVY CHAIN HUMANIZED FUSED TO IFN.ALPHA.2B (1-612) (VH (HOMO SAPIENS IGHV1-69-2*01 (90.7%)-(IGHD)-IGHJ4*01 (85.7%)) CDRIMGT (8.8.13) (26-33.51-58.97-109) (1-120)-HOMO SAPIENS IGHG4*01, G4V5 H P10 (CH1 (121-218), HINGE 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(121-447), FUSED TO IFN.ALPHA.2B K23>R (470), T106>A (553), A145>D (592) (448-612)),(134-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-33*01 (83.2%)-IGKJ4*01 (100%)) CDR-IMGT (6.3.9) (27-32.50-52.89-97) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (226-226'':229-229'')-BISDISULFIDE; PRODUCED IN CHINESE HAMSTER OVARY (CHO) K1SV CELLS, GLYCOFORM ALFA is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →